Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New registry aims to perfect heart ablation workflow

NCT ID NCT06656884

Knowledge-focused Sponsor: Boston Scientific Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 3 times

Summary

This registry is collecting data from over 500 patients with atrial fibrillation who are treated with the FARAPULSE ablation system in routine care. The goal is to identify which pre-procedure, procedure, and follow-up steps work best for different types of patients. Researchers will look at how patient characteristics, procedure choices, and safety events relate to long-term success.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FARAPULSE Pulsed Field Ablation System
What this could lead to
If successful, this study could help doctors standardize the best way to use the FARAPULSE device for treating atrial fibrillation, potentially improving patient outcomes.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may vary across hospitals and patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

524 people

The number who actually took part.

Started

May 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

• Subjects who will undergo an ablation procedure with the FARAPULSE™ Pulsed Field Ablation system, per physician's medical judgement, and according to hospitals' standard of care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects are prospectively planned and intended to be treated with the FARAPULSE™ Pulsed Field Ablation system for cardiac tissue ablation, per physician's medical judgement, and as per hospitals' standard of care * Subjects who are willing and capable of providing informed consent * Subjects who are willing and capable of participating to this Registry at an approved clinical investigational center * Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law Exclusion Criteria: * Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study. Exceptions are when the subject is participating in a mandatory governmental registry, or a purely observational registry, that do not interfere with the current study * Prior Left Atrium Ablation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF)

Contacts and locations

Locations

  • A.o. Krankenhaus der Elisabethinen Linz

    Linz, Austria

  • Azienda Ospedaliera San Gerardo

    Monza, Italy

  • Azienda Ospedaliero-Universitaria di Ferrara

    Ferrara, Italy

  • CHR de la Citadelle

    Namur, Belgium

  • CHRU Hopital Trousseau

    Tours, France

  • CHU de Bordeaux

    Bordeaux, France

  • Freeman Hospital

    Newcastle upon Tyne, United Kingdom

  • GHP Arytmi Center Stockholm

    Stockholm, Sweden

  • Glenfield Hospital

    Leicester, United Kingdom

  • Hopital Saint Philibert

    Lomme, France

  • Hospital De La Santa Creu I Sant Pau

    Barcelona, Spain

  • Hospital Universitario Nuestra Senora de Candelaria

    Santa Cruz de Tenerife, Spain

  • Hospital de Navarra

    Pamplona, Spain

  • Ippokrateio General Hospital of Athens

    Athens, Greece

  • King Fahd Armed Forces Hospital

    Jeddah, Saudi Arabia

  • Mitera Hospital

    Athens, Greece

  • Munchen Klinik Bogenhausen

    München, Germany

  • Ospedale Dell Angelo

    Mestre, Italy

  • Ospedale San Bortolo di Vicenza Azienda ULSS 8 Berica

    Vicenza, Italy

  • Ospedale di Rivoli

    Rivoli, Italy

  • Papworth Hospital

    Cambridge, United Kingdom

  • Royal Bournemouth Hospital

    Bournemouth, United Kingdom

  • Southampton University Hospital

    Southampton, United Kingdom

  • Staedtisches Klinikum Karlsruhe

    Karlsruhe, Germany

  • Universitaetsklinikum Dusseldorf

    Düsseldorf, Germany

  • University Hospital Virgen Arrixaca

    El Palmar, Spain

  • Ziekenhuis Oost-Limburg

    Genk, Belgium

  • Ziekenhuis aan de Stroom, Middelheim

    Antwerp, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.